At a Glance
- Boehringer Ingelheim India Private Limited enters academic collaboration with National Institute of Pharmaceutical Education and Research, Raebareli
- Partnership emphasizes drug delivery innovation, pharmaceutical technologies, and joint research
- Agreement grants researchers access to the opnMe open-science platform
- Initiative aligns with India’s shift toward an innovation-driven pharmaceutical ecosystem
Written By: Marka Sheshi PharmD
Reviewed By: Pharmacally Editorial Team
Boehringer Ingelheim India Private Limited has signed a Memorandum of Understanding (MoU) with the National Institute of Pharmaceutical Education and Research (NIPER) Raebareli, including its Centre of Excellence for Novel Drug Delivery Systems (CoE-NDDS). This partnership aims to boost academic and research ties in key pharmaceutical areas.
The agreement was formalized at the Department of Pharmaceuticals in Delhi, attended by Shri Manoj Joshi, IAS, Secretary of the Department, along with Shri Awadhesh Kumar Choudhary, Senior Economic Advisor, and Ms. Anugraha P, Director. The event highlights government support for industry-academia collaborations in India’s evolving pharma sector.
The MoU focuses on pharmaceutical technologies, novel drug delivery systems, joint research projects, academic exchanges, and skill-building programs. Boehringer Ingelheim will provide NIPER Raebareli access to opnMe®, its open science portal that connects researchers to speed up healthcare innovations. Plans include symposia, conferences, short-term courses, and scholar engagements to enhance scientific exchange.
Meenal Gauri, Managing Director of Boehringer Ingelheim India, emphasized India’s shift from scale-driven to innovation-led pharma growth, noting that such partnerships accelerate healthcare progress.
Prof. Shubhini A. Saraf, Director of NIPER Raebareli, stated the MoU aligns with their goal to advance education and research in emerging fields like novel drug delivery and community health.
This initiative supports India’s Viksit Bharat 2047 vision by bridging academia and industry to develop skilled talent and patient-centric solutions.
Boehringer Ingelheim India, established in 2003, operates in human pharma and animal health, focusing on diabetes, cardiovascular, and respiratory therapies. NIPER Raebareli strengthens its role in fostering pharma innovation through such strategic alliances.
References
Boehringer Ingelheim India and NIPER Raebareli Sign MoU to Strengthen Pharmaceutical Education and Research Collaboration. February 19, 2026, Boehringer Ingelheim India and NIPER Raebareli sign MoU to strengthen pharmaceutical education and research collaboration | Boehringer Ingelheim IN